Although childhood high hyperdiploid acute lymphoblastic leukemia is associated with a favorable outcome, 20% of patients still relapse. It is important to identify these patients already at diagnosis to ensure proper risk stratification. We have investigated 11 paired diagnostic and relapse samples with single nucleotide polymorphism array and mutation analyses of FLT3, KRAS, NRAS and PTPN11 in order to identify changes associated with relapse and to ascertain the genetic evolution patterns. Structural changes, mainly cryptic hemizygous deletions, were significantly more common at relapse (Po0.05). No single aberration was linked to relapse, but four deletions, involving IKZF1, PAX5, CDKN2A/B or AK3, were recurrent. On the basis of the genetic relationship between the paired samples, three groups were delineated: (1) identical genetic changes at diagnosis and relapse (2 of 11 cases), (2) clonal evolution with all changes at diagnosis being present at relapse (2 of 11) and (3) clonal evolution with some changes conserved, lost or gained (7 of 11), suggesting the presence of a preleukemic clone. This ancestral clone was characterized by numerical changes only, with structural changes and RTK-RAS mutations being secondary to the high hyperdiploid pattern.
Introduction
High hyperdiploid (51-67 chromosomes) B-cell precursor acute lymphoblastic leukemia (ALL) is the largest genetic subgroup of childhood ALL, comprising 25% of all such cases. Cytogenetically, high hyperdiploid ALLs are characterized by a nonrandom gain of chromosomes, in particular X, 4, 6, 10, 14, 17, 18 and 21. In addition, microdeletions of CDKN2A, ETV6, IKZF1, PAX5, RB1 and TCF3, and mutations in the FLT3, KRAS, NRAS and PTPN11 genes, all involved in the RTK-RAS signaling pathway, are relatively frequent. 1 In recent larger series of children with high hyperdiploid ALL, the event-free survival and overall survival rates have been B80 and 90%, respectively. [2] [3] [4] Thus, despite the generally very good prognosis, a substantial proportion of the cases relapse and some patients succumb to the disease. It is of utmost clinical importance to identify these patients up-front in order to assign them to correct risk groups and hence proper treatment regimens. One approach would be to identify specific relapseassociated genetic features already at the time of diagnosis. It has previously been suggested that high hyperdiploid ALLs with structural chromosome changes are associated with a poor outcome; however, this has not been confirmed in later studies. 3, [5] [6] [7] In fact, there are no genetic changes, including microdeletions and mutated genes, known to correlate with relapse in high hyperdiploid ALL. In contrast, several investigators have identified 'favorable' aberrations, reporting a superior outcome for cases harboring certain trisomies, that is, þ 4, þ 10, þ 17 and þ 18; 2, 3, 8, 9 findings that are now used for risk stratification, at least by the Children's Oncology Group with regard to triple trisomies þ 4, þ 10 and þ 17. 10 Another approach to identify genetic changes associated with relapse of high hyperdiploid ALL is to compare the genetic features of paired diagnostic and relapse samples. This would also provide valuable information with regard to the temporal order of the various chromosome abnormalities and gene mutations and thus enable identification of 'preleukemic' ancestral clones as well as secondary, progressionrelated changes. Considering the high incidence of high hyperdiploid ALL, surprisingly, few patients have been analyzed in this respect. In fact, only two studies, both using single nucleotide polymorphism (SNP) array analyses, of paired diagnostic and relapse samples have been published, comprising a total of eight high hyperdiploid ALLs. 11, 12 The two patients analyzed by Yang et al.
11 displayed identical numbers of gains and losses at diagnosis and relapse, providing no evidence for genetic clonal evolution at disease recurrence, whereas Mullighan et al. 12 observed differences in copy number alterations (CNAs) in diagnostic and relapse samples in five of the six cases analyzed. Thus, available data are contradictory with regard to genetic heterogeneity or homogeneity between high hyperdiploid ALLs at diagnosis and relapse, and further studies are clearly needed to clarify this biologically and clinically important issue. In this investigation, we used 500k SNP arrays to analyze paired samples from 11 children with high hyperdiploid ALL, the largest series to date, and also screened for mutations in the RTK-RAS genes FLT3, KRAS, NRAS and PTPN11. Apart from a very recent study on the secondary nature of PTPN11 mutations in high hyperdiploid ALLs, 13 a similar screening has previously not been performed in relapse samples.
Materials and methods

Patient samples
Diagnostic and relapse samples from 11 children with high hyperdiploid ALL were included in the study ( 
SNP array analyses
The SNP array analyses were performed using the Affymetrix (Santa Clara, CA, USA) GeneChip Human 250k Nsp, 250k Sty and 10k 2.0 array systems. These arrays cover B510 000 SNPs, with a median physical distance between the SNPs of o2.5 kb. Hybridization and washes were performed as previously described. 14 The Affymetrix GTYPE software was used for analysis of signal intensity and for genotype calling. Apart from copy number analysis, the genotype data were also used to confirm that the diagnostic and relapse samples were derived from the same individual. As an initial step to identify putative genomic imbalances, log 2 ratios were segmented with the circular binary segmentation algorithm 15 using the DNA copy package in R (http://www.bioconductor.org). For further and detailed CNA and uniparental isodisomy analyses, the dChip 16 and the in-house Genome Orientated Laboratory File (GOLF) software packages were used. When applying the former software for CNA detection, the median smoothing was set to a 21 SNP window and the sample trimming to 20%, with the function 'scale copy number mode to 2 copy' being used.
Classification as a CNA was based on visual inspection of the inferred log 2 ratio versus the pooled signal intensity of 10 control samples. Ratios X±0.5 were classified as abnormal, with ratios between ± 0.5 and 1.0 interpreted as duplications/ hemizygous deletions and X±1.0 classified as amplifications/ homozygous deletions. Imbalances representing copy number polymorphisms, listed in the Database of Genomic Variants (http://projects.tcag.ca/variation/), or somatic immunoglobulin and T cell receptor gene rearrangements were excluded from further analysis.
Mutation analyses of FLT3, KRAS, NRAS and PTPN11
For analyses of codons 835 and 836 in the second tyrosine kinase domain and of internal tandem duplication of exons 14 and 15 in FLT3, codons 12, 13 and 61 in NRAS and KRAS and of exons 3 and 13 in PTPN11, eight different PCRs were performed, as previously described. 17 For each PCR, B100 ng DNA was used as a template. The PCR products were directly sequenced using the McLAB sequencing service (San Francisco, CA, USA) and both the sense and the antisense strands were sequenced and analyzed using the Seqscape software (PE Applied Biosystems, Foster City, CA, USA).
Results
Comparison of paired diagnostic and relapse samples identifies ancestral clones
On the basis of the genetic relationship between the diagnostic and relapse samples in the 11 patients (Table 1) , three distinct groups were identified ( Figure 1 ): (1) identical genetic changes at diagnosis and relapse (no. 1 and 3; 2 of 11 cases), (2) clonal evolution with all changes at diagnosis being present at relapse (no. 6 and 9; 2 of 11 cases) and (3) ancestral clones with some changes present at diagnosis but not at relapse (no. 2, 4, 5, 7, 8, 10 and 11; 7 of 11 cases), suggesting the presence of a preleukemic clone. 12 In two of the latter cases (no. 2 and 11), cells in fixative were available from both diagnosis and relapse for fluorescent in situ hybridization (FISH) analyses. In case 2, FISH with WCP6 (Applied Spectral Imaging, Migdal Haemek, Israel) and LSI p16 (Vysis-Abott, Des Plaines, IL, USA) confirmed the presence of trisomy 6 (control for high hyperdiploid cell) and a homozygous deletion of CDKN2A at diagnosis; the deletion was not seen at relapse. In case 11, FISH with WCP1 and WCP6 (Applied Spectral Imaging) confirmed trisomy 6 (control as above) and two normal copies of chromosome 1 at diagnosis; at relapse, a derivative chromosome with chromosome 1 material was seen in addition to disomy 1 (confirming the presence of a duplication).
As seen in Table 1 , it can be deduced that the ancestral clones were characterized by numerical changes only, with structural changes and mutated RTK-RAS genes differing between the paired samples.
There were no clear-cut differences with regard to time from diagnosis to relapse among the three groups (41-48, 14-39 and 26-74 months, respectively; Table 1 ).
Patterns of gained chromosomes
The number of gains ranged between 7 and 13 (median 9) among the 11 cases (22 samples), and involved, in decreasing frequency order, chromosomes 6 (100%), 21 (100%), 4 (91%), 17 (91%), 18 (91%), X (86%), 10 (82%), 8 (77%), 14 (45%), 5 (23%), 2 (9%), 7 (9%), 9 (9%), 15 (9%) and 16 (5%). In seven cases (no. 1, 3-6, 9 and 10), the gains were identical at diagnosis and relapse, whereas they differed by 1-5 trisomies/tetrasomies, involving chromosomes X, 5, 8, 14, 16 and 21, in 4 of the 11 patients. There were no major modal shifts in the latter four cases (55-54 in no. 2, 55-58 in no. 7, 59-58 in no. 8 and 57-55 in no. 11; Table 1 ). An acquired uniparental isodisomy was detected in 1 of the 11 cases, comprising a UPD8 at diagnosis and relapse in case 8.
Simultaneous trisomies of chromosomes 4, 10 and 17Fthe triple trisomies used for stratification of patients into a lower-risk group by the Children's Oncology Group 10 Fwere found in 7 of the 11 patients both at diagnosis and at relapse (Table 1) . Abbreviations: D, sample from the time of diagnosis; F, female; M, male; R, sample from the time relapse; SNP, single nucleotide polymorphism; UPD, uniparental isodisomy.
a Genomic imbalances and mutations differing between diagnostic and relapse samples are indicated in bold.
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Microdeletions are significantly more common in relapses
The number of structural changes varied between 0 and 6 (median 3) among the 22 samples. A total of 34 different hemizygous deletions, two homozygous deletions and five copy number gains (whole chromosomes excluded) were identified. The median size of the 36 hemi-and homozygous deletions was 0.156 Mb (range 0.019-66.579 Mb), with both the homozygous deletions being o1 Mb. The median size of the copy number gains was 40.127 Mb (range 0.142-100.895 Mb). Among all 41 structural changes detected, 9 (22%) were 410 Mb in size; the remaining 32 (78%) imbalances would be considered cytogenetically cryptic ( Table 2) . None of the five copy number gains involved the same chromosome regions (Table 1) . Of the 36 hemi-and homozygous deletions identified, 4 were overlapping (although with different breakpoints) in more than one case and were hence recurrent (Table 2): 7p12.2/IKZF1 (no. 4D and 7R), 9p13.2/PAX5 (no. 4D and 10D/R), 9p21.3/CDKN2A/B (no. 2D and 4R) and 9p24.1/AK3 (no. 8R and 10D) (Figure 2) .
None of the homozygous deletions or copy number gains was shared in paired diagnostic and relapse samples, and apart from a homozygous 9p deletion at diagnosis in case 2, these changes were only found at relapse. Among the 34 hemizygous deletions, 9 were seen both at diagnosis and relapse in five patients (no. 1, 4, 5, 10 and 11). Of the remaining 25 hemizygous deletions, 17 (68%) were found at relapse and 8 (32%) at diagnosis (Tables 1 and 2 ). Taken together, the mean frequency of structural changes at diagnosis was 1.6 (median 1.0; range 0-4), whereas the corresponding frequency at relapse was 2.9 (median 3.0; range 0-6) (Po0.05; Wilcoxon matched pairs signed rank-sum test).
Most FLT3, KRAS, NRAS and PTPN11 mutations are found at relapses
Five of the eleven cases harbored a total of six mutated RTK-RAS genes (Table 1) : one FLT3 mutation (no. 8R), two KRAS mutations (no. 6R and 9R) and three PTPN11 mutations (no. 5D, 8D/R and 10R).
Among the six different mutations, one was detected both at diagnosis and relapse (PTPN11 in case 8). Of the remaining five mutations, one was found at diagnosis only (no. 5) and four at relapse only (no. 6, 8, 9 and 10) ( Table 1) .
Discussion
The salient findings in this study of paired diagnostic and relapse samples from childhood high hyperdiploid ALLs are (1) that structural changes were significantly more common in relapse samples, (2) that no single, recurrent aberration could be directly linked to relapse and (3) that there were genetic differences, involving mainly structural abnormalities and mutated RTK-RAS genes, between diagnostic and relapse samples in the vast majority of patients, suggesting the presence of an ancestral high hyperdiploid clone in many of the cases and that structural changes and mutations are secondary to the high hyperdiploid pattern.
Despite the fact that simultaneous occurrence of þ 4, þ 10 and þ 17 in childhood ALL has been associated with low-risk pediatric ALL, 10 we nevertheless found these triple trisomies in the majority (7 of 11; 64%) of the patients who later relapsed (Table 1) , a frequency on a par with the incidence of 55% of these triple trisomies in close to 60 high hyperdiploid cases also analyzed by high-resolution arrays at the time of diagnosis. [18] [19] [20] [21] Thus, it is clear that the triple trisomies are seen in a substantial proportion of relapses of high hyperdiploid ALLs, a finding that may question their favorable prognostic impact.
The frequencies of structural aberrations, mainly cytogenetically cryptic hemizygous deletions, were significantly higher in the relapse samples. This is not unexpected considering that several previous studies, using conventional chromosome banding techniques, have shown increased numbers of structural chromosome abnormalities in ALL, including high hyperdiploid cases, at relapse. [22] [23] [24] [25] [26] [27] Using SNP array analysis, Mullighan et al.
12 also observed significantly higher frequencies of deletions in relapse samples. In this study, most RTK-RAS mutations were detected at relapse. Although not statistically significant, it agrees well with the notion that additional genetic changes are acquired before relapse. Whether these are caused by the previous genotoxic therapy or are a consequence of inherent clonal evolution over time is unknown, and may well be impossible to clarify because ALL treatment is solely based on chemotherapy. However, it should be stressed that Case et al. 28 showed that, using standard PCR and denaturing high performance liquid chromatography, RTK-RAS mutations may seem to arise at relapse; however, highly sensitive allele-specific PCR analyses nevertheless may identify them already at diagnosis, suggesting the presence of the clone that later relapsed already at the time of diagnosis.
There were no structural aberrations or mutated RTK-RAS genes common to all cases (Tables 1 and 2) , showing that there is no single aberration directly linked to relapse, at least not identifiable by the methods used herein. However, four structural abnormalities, namely, the deletions involving AK3, CDKN2A/B, IKZF1 or PAX5, were recurrent in this series, being found in two cases each (Table 2 ). Submicroscopic deletions of these genes have previously been identified at diagnosis as well Figure 1 On the basis of the genetic relationship between the diagnostic and relapse samples, three distinct groups could be delineated: (A) identical clones (2 of 11 cases) at diagnosis and relapse, (B) clonal evolution (2 of 11) with all changes at diagnosis being present at relapse and (C) ancestral clones (7 of 11), that is some changes were conserved and others lost or gained in the diagnostic and relapse samples, respectively. HeH, high hyperdiploidy.
Relapsed high hyperdiploid acute lymphoblastic leukemia J Davidsson et al Table 2 Partial chromosomal imbalances in paired diagnostic and relapsed samples from childhood high hyperdiploid acute lymphoblastic leukemias as at relapse of high hyperdiploid ALLs, 1, 12, 21 but their prognostic impact remains to be clarified, at least in the context of high hyperdiploidy. 29, 30 Recently, deletions of IKZF1 were shown to be a predictor of poor outcome in high-risk pediatric B-cell progenitor ALL. 31 However, high hyperdiploid ALLs are rarely grouped as high risk. 1 Furthermore, of the four high hyperdiploid cases included in the high-risk group reported by Mullighan et al., 31 none had IKZF1 deletions, whereas the frequency of such deletions was B10% (4 of 44) in the validation cohort. In addition, among the present eleven patients and the six informative paired diagnostic and relapse samples previously reported, 12 three harbored IKZF1 deletions, with the deletions being present both at diagnosis and relapse in one case, 12 only at diagnosis in another (no. 4D; Table 2 ) and only at relapse in one case (no. 7R; Table 2 ). Taken together, it seems unlikely that IKZF1 deletions have a major prognostic impact in high hyperdiploid ALL.
For many years, childhood high hyperdiploid childhood ALLs were thought to be genetically characterized only by the nonrandom tri-and tetrasomies and a handful of well-defined structural chromosome abnormalities. However, with the recent advent of array-based screening methods, revealing a more complex pattern with several and heterogeneous submicroscopic aberrations, this view is now changing. 1 In addition, and as clearly seen in the present series (Tables 1 and 2 ) and in the study by Mullighan et al., 12 the complexity increases even further when comparing diagnostic and relapse samples. In fact, the genetic relationship between diagnostic and relapse samples can be divided into three distinct groups (Figure 1 ): identical clones (B20%), unidirectional clonal evolution (B20%) and ancestral clones (B65%). The latter were identifiable by displaying a complex genetic evolution pattern with some changes conserved and others lost or gained and probably correspond to early preleukemic clones from which both the diagnostic and relapse clones emanate (Figure 2) . 12 Although the ancestral clone cannot be directly observed, it is possible to deduce its basic genetic constitution by comparing diagnostic and relapse samples (Tables 1 and 2 ). It then becomes clear that both structural chromosome changes and mutated RTK-RAS genes are secondary to the high hyperdiploid pattern. Considering that high hyperdiploid cells have been detected already at birth in children who subsequently developed high hyperdiploid ALL, 32, 33 these results indicate that structural chromosome abnormalities and FLT3, KRAS, NRAS and
